RxDoctor Payments DataLook up a doctor →

William Loui, MD

Hematology & Oncology · Honolulu, HINPI 1346217718

Payments from drug & device makers

$11,720in general payments, 2019–2025

Across 409 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Astellas Pharma US Inc$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Johnson & Johnson$700
  • E.r. Squibb & Sons, L.L.C.$653
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$8,96576%
  • Education$1,99017%
  • Other$7657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,720 in reported general payments places this provider in the 60th percentile of 42 hematology & oncology providers in Hawaii.

See all hematology & oncology providers in Hawaii

Medicare billing

Part B allowed, 2024
$148,600
Medicare patients
402
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide49$701,487
ImbruvicaIbrutinib29$469,575
CabometyxCabozantinib S-Malate16$412,816
TagrissoOsimertinib Mesylate17$290,549
JakafiRuxolitinib Phosphate21$173,958
Imatinib Mesylate23$78,452
PegasysPeginterferon Alfa-2a14$25,920
XareltoRivaroxaban15$13,531
ArexvyRsvpref3 Antigen/As01e/Pf19$5,498
Raloxifene Hcl42$4,146
Tamoxifen Citrate96$3,595
Anastrozole60$2,750
Hydroxyurea59$2,400
Exemestane23$1,677
Megestrol Acetate15$1,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$1,405$701,48749 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$211$469,57529 claims
Exelixis Inc.Cabometyx$169$412,81616 claims
AstraZenecaTagrisso$1,116$290,54917 claims
Incyte CorporationJakafi$546$173,95821 claims
Genentech, Inc.Pegasys$20$25,92014 claims
Johnson & JohnsonXarelto$700$13,53115 claims
GSKArexvy$82$5,49819 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$23$29915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 42 hematology & oncology providers in Hawaii.

Other hematology & oncology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →